Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases
暂无分享,去创建一个
Claus Christiansen | László B. Tankó | Kim Henriksen | L. Tankó | P. Delmas | P. Qvist | K. Henriksen | Per Qvist | P. D. Delmas | Morten A. Karsdal | M. Karsdal | C. Christiansen | Morten A. Karsdal
[1] M. Karsdal,et al. Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. , 2004, The American journal of pathology.
[2] C. Christiansen,et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.
[3] T. Martin,et al. Hormones in the coupling of bone resorption and formation , 2005, Osteoporosis International.
[4] J. Risteli,et al. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide , 2005, Osteoporosis International.
[5] P. Alexandersen,et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. , 2000, Bone.
[6] M. Karsdal,et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. , 2005, The American journal of pathology.
[7] J. Halleen. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. , 2003, Anticancer research.
[8] M. Econs,et al. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). , 2004, Clinical chemistry.
[9] M. C. Ovejero,et al. The Chloride Channel Inhibitor NS3736 Prevents Bone Resorption in Ovariectomized Rats Without Changing Bone Formation , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] R. Ziegler,et al. Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] P. Delmas,et al. Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] P. Härkönen,et al. Estrogen and bone metabolism. , 1996, Maturitas.
[13] C. Christiansen,et al. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.
[14] J. Finkelstein,et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.
[15] R. Eastell. CHAPTER 27 – Biochemical Markers of Bone Turnover , 2007 .
[16] N. Hamdy. Osteoprotegerin as a potential therapy for osteoporosis , 2005, Current rheumatology reports.
[17] G. Rodan,et al. Mechanism of action of bisphosphonates , 2003, Current osteoporosis reports.
[18] H. Suominen,et al. Tartrate‐Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] K. Hultenby,et al. Proteolytic Excision of a Repressive Loop Domain in Tartrate-resistant Acid Phosphatase by Cathepsin K in Osteoclasts* , 2005, Journal of Biological Chemistry.
[20] P. Plé,et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. , 2004, Journal of medicinal chemistry.
[21] R. Taichman,et al. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. , 2005, Endocrinology.
[22] Mary L Bouxsein,et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.
[23] D. Simmons,et al. Bone cell populations and histomorphometric correlates to function , 1988, The Anatomical record.
[24] T. Martin,et al. Osteoclast-derived activity in the coupling of bone formation to resorption. , 2005, Trends in molecular medicine.
[25] T. Lehtimäki,et al. Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] E. Lanino,et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment , 2005, Journal of Medical Genetics.
[27] T. Chambers,et al. Secretion of tartrate‐resistant acid phosphatase by osteoclasts correlates with resorptive behavior , 2006, Journal of cellular biochemistry.
[28] Tuan V. Nguyen,et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. , 2006, Clinical laboratory.
[29] C. Christiansen,et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. , 1999, The Journal of clinical endocrinology and metabolism.
[30] R. M. Edwards,et al. Evidence for a Major Gene for Bone Mineral Density in Idiopathic Osteoporotic Families , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] R. Eastell,et al. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. , 2004, Bone.
[32] Kim Henriksen,et al. Transforming Growth Factor-β Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression* , 2003, Journal of Biological Chemistry.
[33] L. Mosekilde,et al. Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. , 1993, Bone.
[34] U. Willinger,et al. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? , 2005, The Journal of laboratory and clinical medicine.
[35] G. Cook,et al. Primer on the metabolic bone diseases and disorders of mineral metabolism , 2003 .
[36] R. Heaney,et al. Is the paradigm shifting? , 2003, Bone.
[37] T. Martin,et al. Therapeutic approaches to bone diseases. , 2000, Science.
[38] C. Christiansen,et al. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. , 1999, Bone.
[39] S. Manolagas,et al. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. , 2000, Endocrine reviews.
[40] W. Rifkin. Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.
[41] K. Prestwood,et al. The Effect of Raloxifene on Markers of Bone Turnover in Older Women Living in Long‐Term Care Facilities , 2004, Journal of the American Geriatrics Society.